Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience

Danuta Rosińska; Grażyna Chodorowska; Jadwiga Roszkiewicz; Magdalena Czarnecka-Operacz; Monika Kapińska-Mrowiecka; Waldemar Placek; Wojciech Silny

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2005
vol. 22

Send email

Copy url:

abstract:

Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience

Danuta Rosińska

,

Grażyna Chodorowska

,

Jadwiga Roszkiewicz

,

Magdalena Czarnecka-Operacz

,

Monika Kapińska-Mrowiecka

,

Waldemar Placek

,

Wojciech Silny

PDiA 2005; XXII, 1: 1–9

Online publish date: 2005/02/16

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Rosińska D, Chodorowska G, Roszkiewicz J, et al. Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2005;22(1):1-9.

APA

Rosińska, D., Chodorowska, G., Roszkiewicz, J., Czarnecka-Operacz, M., Kapińska-Mrowiecka, M.,  & Placek, W. et al. (2005). Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 22(1), 1-9.

Chicago

Rosińska, Danuta, Grażyna Chodorowska, Jadwiga Roszkiewicz, Magdalena Czarnecka-Operacz, Monika Kapińska-Mrowiecka, Waldemar Placek,  and Wojciech Silny. 2005. "Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 22 (1): 1-9.

Harvard

Rosińska, D., Chodorowska, G., Roszkiewicz, J., Czarnecka-Operacz, M., Kapińska-Mrowiecka, M., Placek, W.,  and Silny, W. (2005). Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 22(1), pp.1-9.

MLA

Rosińska, Danuta et al. "Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 22, no. 1, 2005, pp. 1-9.

Vancouver

Rosińska D, Chodorowska G, Roszkiewicz J, Czarnecka-Operacz M, Kapińska-Mrowiecka M, Placek W et al. Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2005;22(1):1-9.

Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease. Strong need for safe and effective anti-
-inflammatory agents in the treatment of AD patients resulted in invention of a new group of therapeutics — calcineurine inhibitors.
The aim of the study was to evaluate efficacy and safety of Pimecrolimus (cream 1%) in the short term treatment of AD patients.
We investigated 76 children aged from 6 to 10 years presenting mild or moderate type of the disease. Patients were clinically evaluated according to IGA (Investigator Global Assessment) index before treatment and after 15 and 29 days of therapy. We also evaluated skin pruritus in the scale of 0 to 3 points.
At the starting point of the trial most patients presented mild (48.7%) or moderate (47.4%) skin inflammation. After 4 weeks of treatment majority of patients were nearly asymptomatic (52.8%) or clear of skin lesions (27.8%). Differences of clinical evaluations were statistically significant (p<0.001). Before treatment skin pruritus was evaluated as moderate in 56.6% of cases and after 4 weeks of therapy most patients reported mild intensity of itching sensation (47.2%). The difference was statistically significant (p<0.001).
We were able to present that pimecrolimus is an effective topical anti-inflammatory agent which reduces skin pruritus in the treatment of AD patients.

keywords:

Evaluation of clinical efficacy and safety of Pimecrolimus (cream 1%) in the treatment of patients with atopic dermatitis – polish experience

Danuta Rosińska , Grażyna Chodorowska , Jadwiga Roszkiewicz , Magdalena Czarnecka-Operacz , Monika Kapińska-Mrowiecka , Waldemar Placek , Wojciech Silny

atopic dermatitis, calcineurin inhibitors, pimecrolimus

Danuta Rosińska

,

Grażyna Chodorowska

,

Jadwiga Roszkiewicz

,

Magdalena Czarnecka-Operacz

,

Monika Kapińska-Mrowiecka

,

Waldemar Placek

,

Wojciech Silny